Palmoplantar Pustulosis Induced by Intravenous Anifrolumab: An Emerging Dermatologic Adverse Event?
Dermatology Practical & Conceptual · 31.07.2026 · 16 (3) · 6789
DOI: 10.5826/dpc.1603a6789 ↗Kurz gefasst
Leserbrief in der Zeitschrift Dermatology Practical & Conceptual, online erschienen am 31.07.2026. Verfasst von Silvia Zanghì und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Spedali Civili, University of Brescia, Brescia, Italy. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
formation. The granular layer appears irregular, while the stratum corneum displays superficial orthokeratotic hyperkeratosis and compact parakeratosis in the deeper portion. Dermal papillae are elongated with vertical capillary orientation. A moderately dense mononuclear inflammatory infiltrate is present, predominantly localized at the base of the vesiculo-pustules, associated with focal erythrocyte extravasation. The infiltrate is perivascular and interstitial. Periodic acid–Schiff staining was negative for fungal elements (EE,10x).
Autor:innen und Institutionen
- Department of Dermatology, Spedali Civili, University of Brescia, Brescia, Italy.
- Pathology Department, University of Brescia, ASST Spedali Civili di Brescia, Italy.
Zitieren
APA
Zanghì, S., Bighetti, S., Bettolini, L., Ghini, I., Rossi, M., & Maione, V. (2026). Palmoplantar Pustulosis Induced by Intravenous Anifrolumab: An Emerging Dermatologic Adverse Event?. Dermatology Practical & Conceptual, 16(3), 6789. https://doi.org/10.5826/dpc.1603a6789
Vancouver
Zanghì S, Bighetti S, Bettolini L, Ghini I, Rossi M, Maione V. Palmoplantar Pustulosis Induced by Intravenous Anifrolumab: An Emerging Dermatologic Adverse Event?. Dermatology Practical & Conceptual. 2026;16(3):6789. doi:10.5826/dpc.1603a6789
BibTeX
@article{Zangh2026,
author = {Zanghì, Silvia and Bighetti, Stefano and Bettolini, Luca and Ghini, Iacopo and Rossi, Mariateresa and Maione, Vincenzo},
title = {Palmoplantar Pustulosis Induced by Intravenous Anifrolumab: An Emerging Dermatologic Adverse Event?},
journal = {Dermatology Practical & Conceptual},
year = {2026},
volume = {16},
number = {3},
pages = {6789},
doi = {10.5826/dpc.1603a6789}
}
EUVIMED